Effect of Kappa-opioid Receptor Agonists U69593, U50488H, Spiradoline and Salvinorin A on Cocaine-induced Drug-seeking in Rats
Overview
Pharmacology
Psychology
Social Sciences
Affiliations
Our previous work indicated that pretreatment with the selective kappa-opioid receptor (KOPr) agonist, U69593, attenuated the ability of priming injections of cocaine to reinstate extinguished cocaine-seeking behavior. The present study expanded these initial tests to include other traditional KOPr agonists, U50488H, spiradoline (SPR), and salvinorin A (Sal A), an active constituent of the plant Salvia divinorum. Following acquisition and stabilization of cocaine self-administration, cocaine-produced drug-seeking was measured. This test was conducted in a single day and comprised an initial phase of self-administration, followed by a phase of extinguished responding. The final phase examined reinstatement of extinguished cocaine self-administration followed by a priming injection of cocaine (20.0mg/kg, intraperitoneal (I.P.)) in combination with the various KOPr agonists. Cocaine-induced drug-seeking was attenuated by pretreatment with U69593 (0.3mg/kg, subcutaneous (S.C.)), U50488H (30.0mg/kg, I.P.), SPR (1.0, 3.0mg/kg, I.P.) and Sal A (0.3, 1.0mg/kg, I.P.). Sal A (0.3, 1.0mg/kg, I.P.) had no effect on operant responding to obtain sucrose reinforcement or on cocaine-induced hyperactivity. These findings show that Sal A, like other traditional KOPr agonists attenuates cocaine-induced drug-seeking behavior.
Huskinson S, Platt D, Smith Z, Doyle W, Zamarripa C, Dunaway K Drug Alcohol Depend. 2023; 252:110953.
PMID: 37734282 PMC: 10615792. DOI: 10.1016/j.drugalcdep.2023.110953.
van de Wetering R, Ewald A, Welsh S, Kornberger L, Williamson S, McElroy B Molecules. 2023; 28(12).
PMID: 37375403 PMC: 10304272. DOI: 10.3390/molecules28124848.
Therapeutic Potential of Salvinorin A and Its Analogues in Various Neurological Disorders.
Cichon J, Liu R, Le H Transl Perioper Pain Med. 2022; 9(2):452-457.
PMID: 35959414 PMC: 9364973.
The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.
Dalefield M, Scouller B, Bibi R, Kivell B Front Pharmacol. 2022; 13:837671.
PMID: 35795569 PMC: 9251383. DOI: 10.3389/fphar.2022.837671.
Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.
Zhou Y, Freeman K, Setola V, Cao D, Kaski S, Kreek M Handb Exp Pharmacol. 2021; 271:137-162.
PMID: 33834276 PMC: 9249371. DOI: 10.1007/164_2021_443.